scholarly journals Efficiency of Bridging-Sheet Recruitment Explains HIV-1 R5 Envelope Glycoprotein Sensitivity to Soluble CD4 and Macrophage Tropism

2012 ◽  
Vol 87 (1) ◽  
pp. 187-198 ◽  
Author(s):  
O. O'Connell ◽  
A. Repik ◽  
J. D. Reeves ◽  
M. P. Gonzalez-Perez ◽  
B. Quitadamo ◽  
...  
Retrovirology ◽  
2008 ◽  
Vol 5 (1) ◽  
pp. 89 ◽  
Author(s):  
Fiorella Rossi ◽  
Bianca Querido ◽  
Manideepthi Nimmagadda ◽  
Simon Cocklin ◽  
Sonia Navas-Martín ◽  
...  

1999 ◽  
Vol 73 (5) ◽  
pp. 4360-4371 ◽  
Author(s):  
Mark T. Esser ◽  
Toshiyuki Mori ◽  
Isabelle Mondor ◽  
Quentin J. Sattentau ◽  
Barna Dey ◽  
...  

ABSTRACT Cyanovirin-N (CV-N), an 11-kDa protein isolated from the cyanobacterium Nostoc ellipsosporum, potently inactivates diverse strains of human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. While it has been well established that the viral surface envelope glycoprotein gp120 is a molecular target of CV-N, the detailed mechanism of action is of further interest. We compared matched native and CV-N-treated virus preparations in a panel of assays that measure viral replication, assessing successive stages of the viral life cycle. CV-N-treated virions failed to infect cells as detected by p24 production and quantitative PCR for HIV-1 reverse transcription products, whereas treatment of the target cells did not block infection, confirming that CV-N acts at the level of the virus, not the target cell, to abort the initial infection process. Compared to native HIV-1 preparations, CV-N-treated HIV-1 virions showed impaired CD4-dependent binding to CD4+ T cells and did not mediate “fusion from without” of CD4+ target cells. CV-N also blocked HIV envelope glycoprotein Env-induced, CD4-dependent cell-cell fusion. Mapping studies with monoclonal antibodies (MAbs) to defined epitopes on the HIV-1 envelope glycoprotein indicated that CV-N binds to gp120 in a manner that does not occlude or alter the CD4 binding site or V3 loop or other domains on gp120 recognized by defined MAbs and does not interfere with soluble CD4-induced conformational changes in gp120. Binding of CV-N to soluble gp120 or virions inhibited subsequent binding of the unique neutralizing MAb 2G12, which recognizes a glycosylation-dependent epitope. However, prior binding of 2G12 MAb to gp120 did not block subsequent binding by CV-N. These results help clarify the mechanism of action of CV-N and suggest that the compound may act in part by preventing essential interactions between the envelope glycoprotein and target cell receptors. This proposed mechanism is consistent with the extensive activity profile of CV-N against numerous isolates of HIV-1 and other lentiviruses and supports the potential broad utility of this protein as a microbicide to prevent the sexual transmission of HIV.


Retrovirology ◽  
2012 ◽  
Vol 9 (Suppl 2) ◽  
pp. P141
Author(s):  
O O'Connell ◽  
A Repik ◽  
JD Reeves ◽  
MP Gonzalez-Perez ◽  
B Quitadamo ◽  
...  
Keyword(s):  
Hiv 1 ◽  

Biochemistry ◽  
1991 ◽  
Vol 30 (16) ◽  
pp. 3916-3922 ◽  
Author(s):  
Glen Teshima ◽  
Jim Porter ◽  
Kalvin Yim ◽  
Victor Ling ◽  
Andrew Guzzetta

1998 ◽  
Vol 72 (8) ◽  
pp. 6332-6338 ◽  
Author(s):  
Nancy Sullivan ◽  
Ying Sun ◽  
James Binley ◽  
Juliette Lee ◽  
Carlos F. Barbas ◽  
...  

ABSTRACT Infection by some human immunodeficiency virus type 1 (HIV-1) isolates is enhanced by the binding of subneutralizing concentrations of soluble receptor, soluble CD4 (sCD4), or monoclonal antibodies directed against the viral envelope glycoproteins. In this work, we studied the abilities of different antibodies to mediate activation of the envelope glycoproteins of a primary HIV-1 isolate, YU2, and identified the regions of gp120 envelope glycoprotein contributing to activation. Binding of antibodies to a variety of epitopes on gp120, including the CD4 binding site, the third variable (V3) loop, and CD4-induced epitopes, enhanced the entry of viruses containing YU2 envelope glycoproteins. Fab fragments of antibodies directed against either the CD4 binding site or V3 loop also activated YU2 virus infection. The activation phenotype was conferred on the envelope glycoproteins of a laboratory-adapted HIV-1 isolate (HXBc2) by replacing the gp120 V3 loop or V1/V2 and V3 loops with those of the YU2 virus. Infection by the YU2 virus in the presence of activating antibodies remained inhibitable by macrophage inhibitory protein 1β, indicating dependence on the CCR5 coreceptor on the target cells. Thus, antibody enhancement of YU2 entry involves neither Fc receptor binding nor envelope glycoprotein cross-linking, is determined by the same variable loops that dictate enhancement by sCD4, and probably proceeds by a process fundamentally similar to the receptor-activated virus entry pathway.


1990 ◽  
Vol 6 (10) ◽  
pp. 1209-1212 ◽  
Author(s):  
RICHARD KIRSH ◽  
TIMOTHY K. HART ◽  
HARMA ELLENS ◽  
JOANNE MILLER ◽  
STEPHEN A. PETTEWAY ◽  
...  

1994 ◽  
Vol 269 (16) ◽  
pp. 12240-12247 ◽  
Author(s):  
E. Decroly ◽  
M. Vandenbranden ◽  
J.M. Ruysschaert ◽  
J. Cogniaux ◽  
G.S. Jacob ◽  
...  

2019 ◽  
Vol 219 (11) ◽  
pp. 1749-1754 ◽  
Author(s):  
Ingrid Karlsson ◽  
Jeanette Linnea Tingstedt ◽  
Gülşen Özkaya Şahin ◽  
Mikkel Hansen ◽  
Zsofia Szojka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document